Try a new search

Format these results:

Searched for:



Total Results:


Psychological aspects of ageing

Chapter by: Schulze, Evan T; Ruppert, Phllip; Heady, Gayle; Schwarz, Lauren
in: Pathy's Principles and Practice of Geriatric Medicine by Sinclair, Alan J; et al (Eds)
[S.l.] : Wiley, 2022
pp. ?-
CID: 5261462

Working Memory, Processing Speed, and Memory Functioning Are Minimally Predictive of Victoria Symptom Validity Test Performance

Resch, Zachary J; Soble, Jason R; Ovsiew, Gabriel P; Castillo, Liliam R; Saladino, Kevin F; DeDios-Stern, Samantha; Schulze, Evan T; Song, Woojin; Pliskin, Neil H
A sound performance validity test is accurate for detecting invalid neuropsychological test performance and relatively insensitive to actual cognitive ability or impairment. This study explored the relationship of several cognitive abilities to several performance indices on the Victoria Symptom Validity Test (VSVT), including accuracy and response latency. This cross-sectional study examined data from a mixed clinical sample of 88 adults identified as having valid neurocognitive test profiles via independent validity measures, and who completed the VSVT along with objective measures of working memory, processing speed, and verbal memory during their clinical neuropsychological evaluation. Results of linear regression analyses indicated that cognitive test performance accounted for 5% to 14% of total variance for VSVT performance across indices. Working memory was the only cognitive ability to predict significant, albeit minimal, variance on the VSVT response accuracy indices. Results show that VSVT performance is minimally predicted by working memory, processing speed, or delayed verbal memory recall.
PMID: 32174137
ISSN: 1552-3489
CID: 5250012

Establishing the base rate of performance invalidity in a clinical electrical injury sample: Implications for neuropsychological test performance

Resch, Zachary J; Paxton, Jessica L; Obolsky, Maximillian A; Lapitan, Franchezka; Cation, Bailey; Schulze, Evan T; Calderone, Veroly; Fink, Joseph W; Lee, Raphael C; Pliskin, Neil H; Soble, Jason R
PMID: 33858295
ISSN: 1744-411x
CID: 5250022

Psychological Assessment and Intervention in Rehabilitation

Chapter by: Soble, JR; Schulze, Evan; Resch, ZJ; Critchfield, EA; O'Rourke, JJF
in: Braddom's Physical Medicine and Rehabilitation by Cifu, David {Ed]
[S.l.] : Elsevier, 2020
pp. ?-
ISBN: 9780323625395
CID: 5261452

Examination of the Minnesota Multiphasic Personality Inventory-2-Restructured Form (MMPI-2-RF) validity and substantive scales in patients with electrical injury

Soble, Jason R; Resch, Zachary J; Schulze, Evan T; Paxton, Jessica L; Cation, Bailey; Friedhoff, Claire; Costin, Colleen; Fink, Joseph W; Lee, Raphael C; Pliskin, Neil H
PMID: 31106672
ISSN: 1744-4144
CID: 5250002

Performance validity testing in a clinical sample of adults with sickle cell disease

Dorociak, Katherine E; Schulze, Evan T; Piper, Lauren E; Molokie, Robert E; Janecek, Julie K
OBJECTIVE:Neuropsychologists utilize performance validity tests (PVTs) as objective means for drawing inferences about performance validity. The Test of Memory Malingering (TOMM) is a well-validated, stand-alone PVT and the Reliable Digit Span (RDS) and Reliable Digit Span-Revised (RDS-R) from the Digit Span subtest of the WAIS-IV are commonly employed, embedded PVTs. While research has demonstrated the utility of these PVTs with various clinical samples, no research has investigated their use in adults with sickle cell disease (SCD), a condition associated with multiple neurological, physical, and psychiatric symptoms. Thus, the purpose of this study was to explore PVT performance in adults with SCD. METHOD: = 40.61, SD = 12.35) were consecutively referred by their hematologist for a routine clinical outpatient neuropsychological evaluation. During the evaluation, participants were administered the TOMM (Trials 1 and 2), neuropsychological measures including the WAIS-IV Digit Span subtest, and mood and behavioral questionnaires. RESULTS:The average score on the TOMM was 47.70 (SD = 3.47, range = 34-50) for Trial 1 and 49.69 (SD = 1.66, range = 38-50) for Trial 2. Only one participant failed Trial 2 of the TOMM, yielding a 98.1% pass rate for the sample. Pass rates at various RDS and RDS-R values were calculated with TOMM Trial 2 performance as an external criterion. CONCLUSIONS:Results support the use of the TOMM as a measure of performance validity for individuals with SCD, while RDS and RDS-R should be interpreted with caution in this population.
PMID: 28632024
ISSN: 1744-4144
CID: 5249992


Chapter by: Janecek, Julie; Puka, Klajdi; Schulze, Evan; Smith, Mary Lou
in: Neuropsychological conditions across the lifespan by Donders, Jacobus; Hunter, Scott J (Eds)
New York, NY : Cambridge University Press, 2018
pp. -
ISBN: 9781107190016
CID: 5261442


Chapter by: Novitski, Julia; Elverman, Kathleen; Kwan, Donna; Schulze, Evan; Grote, Christopher
in: Acquired brain injury : clinical essentials for neurotrauma and rehabilitation professionals by Han, Dong Y (Ed)
New York : Springer Publishing Company, [2017]
pp. 108-132
ISBN: 9780826131362
CID: 5261432

Imaging chronic traumatic brain injury as a risk factor for neurodegeneration

Little, Deborah M; Geary, Elizabeth K; Moynihan, Michael; Alexander, Aristides; Pennington, Michelle; Glang, Patrick; Schulze, Evan T; Dretsch, Michael; Pacifico, Anthony; Davis, Matthew L; Stevens, Alan B; Huang, Jason H
Population-based studies have supported the hypothesis that a positive history of traumatic brain injury (TBI) is associated with an increased incidence of neurological disease and psychiatric comorbidities, including chronic traumatic encephalopathy, Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. These epidemiologic studies, however, do not offer a clear definition of that risk, and leave unanswered the bounding criteria for greater lifetime risk of neurodegeneration. Key factors that likely mediate the degree of risk of neurodegeneration include genetic factors, significant premorbid and comorbid medical history (e.g. depression, multiple head injuries and repetitive subconcussive impact to the brain, occupational risk, age at injury, and severity of brain injury). However, given the often-described concerns in self-report accuracy as it relates to history of multiple TBIs, low frequency of patient presentation to a physician in the case of mild brain injuries, and challenges with creating clear distinctions between injury severities, disentangling the true risk for neurodegeneration based solely on population-based studies will likely remain elusive. Given this reality, multiple modalities and approaches must be combined to characterize who are at risk so that appropriate interventions to alter progression of neurodegeneration can be evaluated. This article presents data from a study that highlights uses of neuroimaging and areas of needed research in the link between TBI and neurodegenerative disease.
PMID: 24924670
ISSN: 1552-5279
CID: 5249982

Thalamic projection fiber integrity in de novo Parkinson disease

Planetta, P J; Schulze, E T; Geary, E K; Corcos, D M; Goldman, J G; Little, D M; Vaillancourt, D E
BACKGROUND AND PURPOSE/OBJECTIVE:Postmortem studies of advanced PD have revealed disease-related pathology in the thalamus with an apparent predilection for specific thalamic nuclei. In the present study, we used DTI to investigate in vivo the microstructural integrity of 6 thalamic regions in de novo patients with PD relative to healthy controls. MATERIALS AND METHODS/METHODS:Forty subjects (20 with early stage untreated PD and 20 age- and sex-matched controls) were studied with a high-resolution DTI protocol at 3T to investigate the integrity of thalamic nuclei projection fibers. Two blinded, independent raters drew ROIs in the following 6 thalamic regions: AN, VA, VL, DM, VPL/VPM, and PU. FA values were then calculated from the projection fibers in each region. RESULTS:FA values were reduced significantly in the fibers projecting from the AN, VA, and DM, but not the VPL/VPM and PU, in the PD group compared with the control group. In addition, there was a reduction in FA values that approached significance in the VL of patients with PD. These findings were consistent across both raters. CONCLUSIONS:The present study provides preliminary in vivo evidence of thalamic projection fiber degeneration in de novo PD and sheds light on the extent of disrupted thalamic circuitry as a result of the disease itself.
PMID: 22766668
ISSN: 1936-959x
CID: 5261412